Arca Biopharma Inc (NASDAQ:ABIO) shares traded 1.47% up during most recent session to reach at the closing price of $0.41. The stock exchanged hands 2.17 Million shares versus average trading capacity of 958.81 Million shares, yielding a market cap of $7.91 Million. Wall Street analysts covering the stock are projecting that the stock will reach $0.9 within the next 52-weeks. The mean target projections are based on 1 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Arca Biopharma Inc (NASDAQ:ABIO) high price target of $0.9 and with a conservative view have low price target of $0.9.

Dawson James “Initiates Coverage on” Arca Biopharma Inc (NASDAQ:ABIO) in a research note issued to investors on 10/09/13 to Buy with price target of $3.8.

On the other hand the company has Relative Strength Index (RSI 14) of 45.76 along with Average True Range (ATR 14) of 0.06, Consequently Arca Biopharma Inc (NASDAQ:ABIO)’s weekly and monthly volatility is 7.14%, 17.95% respectively. The company’s beta value is at 2.09.

In terms of Buy, Sell or Hold recommendations, Arca Biopharma Inc (NASDAQ:ABIO) has analysts’ mean recommendation of 0. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Arca Biopharma Inc (NASDAQ:ABIO)’s minimum EPS for the current quarter is at $-0.11 and can go high up to $-0.11. The consensus mean EPS for the current quarter is at $-0.11 derived from a total of 1 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.2 earnings per share for the same quarter during last year.

Previously Arca Biopharma Inc (NASDAQ:ABIO) reported $-0.1 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.14 by $0.04. The company posted an earnings surprise of 28.6%.

Currently Arca Biopharma Inc (NASDAQ:ABIO)’s shares owned by insiders are 0.89%, whereas shares owned by institutional owners are 11.7%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 2.95%.

Arca Biopharma Inc (NASDAQ:ABIO)’s trailing twelve month revenues are $0, whereas its price to sales ratio for the same period is 0. Its book value per share for the most recent quarter is $0.43 while its price to book ratio for the same period is 0.97, as for as the company’s cash per share for the most recent quarter is $0.35, however its price to cash per share ratio for the same period is 1.2. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.